Literature DB >> 33200331

The Modified Fisher Scale Lacks Interrater Reliability.

Christopher Melinosky1, Hope Kincaid2, Jan Claassen3, Gunjan Parikh4, Neeraj Badjatia4, Nicholas A Morris4.   

Abstract

BACKGROUND: The modified Fisher scale (mFS) is a critical clinical and research tool for risk stratification of cerebral vasospasm. As such, the mFS is included as a common data element by the National Institute of Neurological Disorders and Stroke SAH Working Group. There are few studies assessing the interrater reliability of the mFS.
METHODS: We distributed a survey to a convenience sample with snowball sampling of practicing neurointensivists and through the research survey portion of the Neurocritical Care Society Web site. The survey consisted of 15 scrollable CT scans of patients with SAH for mFS grading, two questions regarding the definitions of the scale criteria and demographics of the responding physician. Kendall's coefficient of concordance was used to determine the interrater reliability of mFS grading.
RESULTS: Forty-six participants (97.8% neurocritical care fellowship trained, 78% UCNS-certified in neurocritical care, median 5 years (IQR 3-6.3) in practice, treating median of 80 patients (IQR 50-100) with SAH annually from 32 institutions) completed the survey. By mFS criteria, 30% correctly identified that there is no clear measurement of thin versus thick blood, and 42% correctly identified that blood in any ventricle is scored as "intraventricular blood." The overall interrater reliability by Kendall's coefficient of concordance for the mFS was moderate (W = 0.586, p < 0.0005).
CONCLUSIONS: Agreement among raters in grading the mFS is only moderate. Online training tools could be developed to improve mFS reliability and standardize research in SAH.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.

Entities:  

Keywords:  Aneurysmal subarachnoid hemorrhage; Cerebral aneurysm; Cerebral ischemia; Cerebral vasospasm; Computed tomography; Computerized tomography (CT); Intracranial hemorrhage; Intracranial vasospasm; Neuroimaging; Reproducibility of results

Mesh:

Year:  2020        PMID: 33200331     DOI: 10.1007/s12028-020-01142-8

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  1 in total

Review 1.  A clinical review of cerebral vasospasm and delayed ischaemia following aneurysm rupture.

Authors:  Nicholas Dorsch
Journal:  Acta Neurochir Suppl       Date:  2011
  1 in total
  6 in total

Review 1.  Aneurysmal Subarachnoid Hemorrhage.

Authors:  David Y Chung; Mohamad Abdalkader; Thanh N Nguyen
Journal:  Neurol Clin       Date:  2021-03-31       Impact factor: 3.806

2.  Applying Quantitative Radiographic Image Markers to Predict Clinical Complications After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.

Authors:  Gopichandh Danala; Masoom Desai; Bappaditya Ray; Morteza Heidari; Sai Kiran R Maryada; Calin I Prodan; Bin Zheng
Journal:  Ann Biomed Eng       Date:  2022-02-02       Impact factor: 3.934

3.  Systemic Immune-Inflammation Index Predicts Delayed Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Joseph R Geraghty; Tyler J Lung; Yonatan Hirsch; Eitan A Katz; Tiffany Cheng; Neil S Saini; Dilip K Pandey; Fernando D Testai
Journal:  Neurosurgery       Date:  2021-11-18       Impact factor: 5.315

4.  Admission Homocysteine as a Potential Predictor for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Tiesong Zhang; Luyuan Zhang; Kehui Nie; Jun Yang; Haiyan Lou; Jincheng Wang; Sicong Huang; Chenjie Gu; Min Yan; Renya Zhan; Jianwei Pan
Journal:  Front Surg       Date:  2022-02-08

5.  Development of central venous access device-associated skin impairment assessment instrument.

Authors:  Min Liu; Chonghao Zheng; Xiangyun Guan; Ziwei Ke; Ping Zou; Yeqin Yang
Journal:  Nurs Open       Date:  2022-05-03

6.  The effect of higher versus lower protein delivery in critically ill patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Zheng-Yii Lee; Cindy Sing Ling Yap; M Shahnaz Hasan; Julia Patrick Engkasan; Mohd Yusof Barakatun-Nisak; Andrew G Day; Jayshil J Patel; Daren K Heyland
Journal:  Crit Care       Date:  2021-07-23       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.